Genentech, the U.S.-based pioneering biotechnology company owned by Switzerland-based Roche, has been at the forefront of the development of complex biologic medicines used to treat conditions ranging from cancer to multiple sclerosis. It recently joined more than a dozen other pharmaceutical companies in striking a deal with the U.S. Administration to slash prices of some prescription medicines for some government programs and offer its flu medicines directly to customers via the new TrumpRx.gov website. Magargee, who has helmed Genentech for two years, joined fellow health industry CEOs and President Trump for the White House announcement.Â
Reuters Global Pharma Editor Michele Gershberg sits down with Magargee at Pharma USA 2026 in Philadelphia to discuss the sweeping shifts underway in U.S. and global health policy, the growing influence of AI on drug discovery and regulatory pathways, and the next generation of promising treatments poised to reshape medical practice. Â
